

Artificial Intelligence in Drug Design and Synthesis



Dr. Balakumar Chandrasekaran **M. Pharm, PhD, PostDoc**
Professor-Faculty of Pharmacy
Philadelphia University-Jordan

Artificial Intelligence (AI)

- AI is a **technology-based system** involving various advanced tools and networks that can **mimic human intelligence**.
- AI utilizes **systems and software** that can interpret and learn from the input data to make independent decisions for accomplishing specific objectives.
- AI involves several method domains like reasoning, knowledge representation, solution search, and **machine learning (ML)**.
- A subfield of the ML is **deep learning (DL)**, which engages artificial neural networks (ANNs).

Artificial Intelligence: History

1971: Research Resource on Computers in Medicines

2015: Pharmbot was Developed
2018-2020: AI Trials in Gastroenterology

1950: Development of Turning Test

2000: Deep Learning was Introduced

2010: CAD Applied to Endoscopy


2007: DeepQA Technology

2017: First FDA Approved Cloud-Based DL Application

1975: First NIH Sponsored AIM Workshop




Artificial Intelligence: Classification



Artificial Intelligence: Application areas


Any technique which enables computers to mimic human brain.

Artificial intelligence



Machine learning

It is simply a data analysis method that automates analytical model building using algorithms that iteratively learn from data. Computers can identify hidden insights without being explicitly programmed.



Deep learning

It is a deeper subset of AI that processes data and creates patterns for decision making purposes. It comprises networks which are capable of learning from unstructured data.


Artificial Intelligence

- These comprise a set of interconnected sophisticated computing elements involving ‘perceptrons’ analogous to human biological neurons, mimicking the transmission of electrical impulses in the human brain.


➤ International Business Machine (IBM)

➤ Watson supercomputer (IBM, New York, USA).

➤ Suggesting treatment strategies for cancer and its detection.



Artificial Intelligence in Drug Discovery



AI in Drug Discovery

Drug
Design

Synthesis

Drug
repurposing

Pharmacolo
gy

Predict
target prt

Pdt Yield

Predict new
target

Predict
activity

Predict prt-
drug
interaction

Rxn
Mechanism

Predict new
use

Predict
toxicity


Predict
activity

Synthetic
route

Design new
drug

Predict
Physico-
chem prop

AI in Drug Design & Synthesis



FOUR CRUCIAL STAGES: 1. Design, 2. Synthesis, 3. Testing,
4. Analyzing of new drugs.

AI in Drug Design: Prediction tools for target protein structures

- AlphaFold: <https://deepmind.com/blog/alphafold>

It is based on deep neural network (DNN)

It is used to analyze the distance between the adjacent amino acids and the corresponding angles of the peptide bonds.

- PotentialNet:-

<https://pubs.acs.org/doi/full/10.1021/acscentsci.8b00507>


It is based on neural network (NN).

It is used to predict the binding affinity of the ligand.


- DeltaVina: <https://github.com/chengwang88/deltavina>

It is a scoring function for rescoring drug–ligand binding affinity.

Prediction tools for target protein structures: Conventional techniques




Prediction tools for target protein structures: Recurrent Geometric network (RGN)



- Protein sequences are fed one residue at a time to the computational units of an RGN. [*Cell Systems* 2019, 8, 292].
- Based on these computations, torsional angles are predicted and fed to geometric units.
- dRMSD is used to measure deviation from experimental structures, serving as the signal for optimizing RGN.

Prediction of drug-protein interactions: (i) Random Forest (RF)

(ii) Support Vector Machine (SVM).



Flow chart of the modeling process.

Prediction of drug-protein interactions: (i) Random Forest (RF)

(ii) Support Vector Machine (SVM).

Predicted results for a model in RF

Dataset	SE (RF/BGL)	SP(RF/BGL)	CO(RF/BGL)	AUC(RF/BGL)
Enzyme	35.82%/57.40%	82.70%/99.50%	59.26%/---	67.43/90.40
GPCR	80.31%/23.40%	55.64%/99.90%	67.98%/---	72.95/89.90
Ion channel	54.09%/27.10%	73.38%/99.60%	63.73%/---	66.58/85.10
Nuclear receptor	91.57%/14.80%	39.76%/99.90%	65.66%/---	82.29/84.30
Average	47.51%/---	74.93%/---	61.64%/---	66.68/---

Dataset: DrugBank database

Descriptor: DRAGON

PROFEAT WEBSEVER

Random Forest algorithm

SE: sensitivity

SP: specificity

CO: compound-protein pairs

BGL: Bipartite graph learning


Predicted results for top 5 scoring novel drug-target interactions

Protein name (UniProt ID)	Drug generic name (DrugBank ID)	Binding score
NAD(P)H dehydrogenase [quinone] 1 (P15559)	Flavin-N7 protonated-adenine dinucleotide (DB02332)	0.996
NAD(P)H dehydrogenase [quinone] 1 (P15559)	NADH (DB00157)	0.994
Alcohol dehydrogenase [NADP+] (P14550)	NADH (DB00157)	0.992
Prostaglandin G/H synthase 1 (P23219)	Bromfenac (DB00963)	0.992
Prostaglandin G/H synthase 1 (P23219)	D-allopyranose (DB03989)	0.990

Novel Target Prediction for an existing drug: MDMA

3,4-Methylene-dioxy-methamphetamine (MDMA)

Psychoactive drug



Predicted top 5 scoring target proteins for the same drug MDMA

Protein name	UniProt ID	Binding score
Beta-1 adrenergic receptor	P08588	0.820
Carbonic anhydrase 2	P00918	0.810
Prothrombin	P00734	0.804
Alpha-2A adrenergic receptor	P08913	0.802
Prostaglandin G/H synthase 2	P35354	0.800
Dipeptidyl peptidase 4	P27284	0.798

Novel Drug Prediction for an existing target:


Thymidine kinase

Predicted top 10 scoring drugs for the same target: Thymidine kinase


Drug generic name	DrugBank ID	Binding score
NADH	DB00157	0.870
Nicotinamide-Adenine-Dinucleotide	DB01907	0.848
Adenosine-5'-Diphosphate	DB03431	0.844
Guanosine-5'-Diphosphate	DB04315	0.808
Acetate Ion	DB04184	0.792
Mesoheme	DB02577	0.786
Heme	DB03014	0.786
Idoxuridine	DB00249	0.762
Pentostatin	DB00552	0.656
1-Beta-Ribofuranosyl-1,3-Diazepinone	DB03185	0.622

[*PLoS One* **2012**, 7, e37608].


Software tools for Drug-Receptor Interaction Prediction




iDrug-GPCR:
The web-server for predicting the interaction between GPCRs and drugs in cellular networking.



iDrug-Chl:
The web-server for predicting the interaction between ion channels and drugs in cellular networking.



iDrug-Ezy:
The web-server for predicting the interaction between enzymes and drugs in cellular networking.



iDrug-NR:
The web-server for predicting the interaction between nuclear receptors and drugs in cellular networking.

[\[http://www.jci-bioinfo.cn/iDrug-Target/\]](http://www.jci-bioinfo.cn/iDrug-Target/)

Prediction of pharmacological activity/affinity of drugs

- DeepNeuralNetQSAR: <https://github.com/Merck/DeepNeuralNet-QSAR>

It utilizes python-based tools and is used to detect molecular activity of a compound.

- Neural graph fingerprint: <https://github.com/HIPS/neural-fingerprint>

It is used to predict the properties of novel molecules.

- DeepTox: www.bioinf.jku.at/research/DeepTox


Software that predicts the toxicity of 12 000 drugs

DeepDTA, PADME, WideDTA, and DeepAffinity are some DL methods used to measure Drug-target binding affinity (DTBA).

PADME: A Deep Learning-based Framework for Drug-Target Interaction Prediction

- ❖ PADME: **P**rotein **A**nd **D**rug **M**olecule interaction pr**E**diction.
- ❖ It is used to predict real-valued **interaction strength** between compounds and proteins.
- ❖ PADME takes both **compound** and **protein** information as inputs to solve cold-target (problems involving target protein that never appeared in the training set) or cold-drug problems.
- ❖ A study by Feng et al., integrated **Molecular Graph Convolution** (MGC) for compound featurization with protein descriptors.
- ❖ Authors used **multiple cross-validation** split schemes and evaluation metrics to measure the performance of PADME.
- ❖ The success of the PADME tool was demonstrated by taking an example of **androgen receptor** (AR) against predicting the binding affinity between various compounds.

Methodology



(a) PADME-ECFP (extended connectivity finger print) architecture.

(b) PADME-GraphConv architecture.


Black dots represent omitted neurons and layers;

CIV: Combined Input Vector.

Compound feature vectors generated using DNN; graph representation of molecules, the atoms are denoted by nodes, while the bonds are denoted by edges.

A case study: Androgen receptor (AR)

- ❖ **Ligands:** US National Cancer Institute human tumour cell line anticancer drug screen data (NCI60), totaling more than 100000.
- ❖ **PADME-ECFP** and **PADME-GraphConv** trained on whole ToxCast dataset.
- ❖ **Average** of their predictions were determined, known as averaged model PADME-Ensemble.
- ❖ **Top 30 compounds** are predicted to bind strongly with AR, out of that **4 compounds** are selected as active.



[[arXiv:1807.09741](#), 2008].

AI in Synthesis of drugs

- **Chempouter:** <https://zenodo.org/record/1481731>

It helps to report procedure for chemical synthesis in standardized format.

- **DeepChem:** <https://github.com/deepchem/deepchem>


It is a multilayer perception (MLP) model that uses a python-based AI system to find a suitable candidate in drug discovery program.

- **ORGANIC:** <https://github.com/aspuru-guzik-group/ORGANIC>

A molecular generation tool that helps to create molecules with desired properties.

- **Chematica and ICSynth:** Regularly used software tools in industries.

AI in Synthesis of drugs




CASP: Computer-aided synthesis planning

AI in Synthesis of drugs: 1. Retrosynthesis


1. Retrosynthesis



2. Condition Recommendation



3. Forward Reaction Prediction



- (1) **Retrosynthesis** can be broken into subproblems of (a) the generation of retrosynthetic suggestions one step at a time and (b) the recursive use of the single step suggestions to identify full, multistep routes.
- (2) **Reaction conditions** that will lead to a successful forward reaction must be recommended.
- (3) **Reaction prediction** of the possible products from a set of starting materials and conditions for the proposed synthetic steps.

- ❖ Expert encoded rules (**first wave-AI**) and ML methods (**second wave-AI**) are AI tools in synthesis.
- ❖ First wave-AI: **Crafted knowledge**
- ❖ Second wave-AI: **Statistical methods**
- ❖ Two categories of methods for scoring compounds by synthesizability: **simplified structure-based** heuristics or full **retrosynthetic tree expansions**.
- ❖ A general procedure for the algorithmic extraction of reaction templates from a reaction data set :
 - (1) identify the **reaction center** or changing atoms
 - (2) identify atoms **adjacent to the reaction** center
 - (3) **add generalized functional** groups involved in the reaction.
- ❖ A single-step retrosynthetic recommender is sufficient to construct routes for one-step reaction at a time.
- ❖ Similarly, it can be extended to derive synthetic route for multistep organic synthesis using a tree search.
- ❖ Each step can produce thousands of precursors.

Retrosynthesis: ICSYNTH Software by InfoChem

ICSYNTH Home Queries ▾ Projects ▾ Assets ▾ Tasks Help ▾ Logout (demosynth) ICSYNTH © InfoChem GmbH, 2007-2017.

Start

New Query

Parameters

Name:

Algorithm:
☒ New
☐ Old
☐ Unprecedented

Mode:
☐ Background


Suggestions (1st Level)

Steps:

Precision:

Strategy

Target:



Libraries


- ☐ CAC (ca 5,300 reactions) (cac_1340_r)
- ☒ Cheminform (ca 1,1M reactions) (cheminform_1340_r)
- ☐ SPRESI singleton reactions (ca 450,000 reactions) (chemsynth2012_1_1340_r)
- ☐ SPRESI reactions 2 examples/ixntype (ca 800,000 reactions) (chemsynth2012_2_1340_r)
- ☐ SPRESI reactions 3+ examples/ixntype (ca 3M reactions) (chemsynth2012_3plus_1340_r)
- ☐ EROS (ca 90,000 reactions) (eros_1340_r)
- ☐ Name reactions (ca 5,000 reactions) (osnamerxn_1340_r)
- ☐ Name reactions (ca 5,000 reactions) (osnamerxn_1350_r)
- ☒ Fundamental Organic Reactions (ca 210,000 reactions) (reflib_1340_r)
- ☐ Science of Synthesis (ca 270,000 reactions) (sos_1340_r)

Comment


-

Search set up: ICSYNTH (rule-based method)

Retrosynthesis: ICSYNTH Software by InfoChem



Retrosynthetic analysis using ASKCOS software




ASKCOS: It proposes the possible synthetic route based on the availability of the starting material.

AI in Synthesis of drugs: 2. Reaction condition planning

Challenges in condition predictions:-

- (1) Amounts, volumes, or concentrations
- (2) Reaction times or kinetics
- (3) Order of the addition of reagents and catalysts



Optimized condition: Pd-catalyzed C–H activation, identified the requirement for both **high temperature** and **polar aprotic** solvents (DMF/DMA) in the top 3 proposed conditions. This was applied to a diverse range of substrate starting materials and observed yields in the range of 39–97%.

AI in Synthesis of drugs: 3. Forward Reaction Prediction

- ❑ To ensure **algorithmic synthesis design** are robust and actionable by anticipating, at least qualitatively, reaction products, forward reaction predictive analysis generally conducted.
- ❑ The **feasibility** of a reaction needs to be determined by searching for similar transformations, **reading the literature**, and determining if the synthetic method will generalize to the substrates of interest.
- ❑ Data-driven techniques can learn to perform the same **generalization** when trained on a broad set of reactions: ML
- ❑ Graph **convolutional neural networks** predict atom and bond changes from starting materials to products.
- ❑ Sequence-to-sequence **models** which predict product SMILES (Simplified Molecular Input Line Entry System).
- ❑ Other methods: **make-on-demand** virtual libraries based on expert-defined reaction templates.

Challenges in Drug Discovery using AI

- ❑ Companies who use AI technology for drug discovery has to go through **vigorous process** to copyright their work so as to secure patent rights.
- ❑ **Security** is also a major concern, as AI-driven personalized medicine requires person's genetic code (legal issues).
- ❑ **Faster computation** will be required for handling big data and it is said that in future the current supercomputers will be replaced by quantum computers.
- ❑ Still **no success story** where a compound generated through AI made it to the market for public use.
- ❑ **Insilico medicine**, a biotechnology company, proposed a novel target involved in idiopathic pulmonary fibrosis and made its novel inhibitor from scratch, through their AI-based tools.
- ❑ The identified small molecule inhibitor has showed good efficacy and applied for **investigational new drug** (IND) in Dec-2020.
- ❑ Expected clinical trials will be **late 2022** by that company.

References

- [1] Paul et al., *Drug Discov. Today*, **2021**, 26, 80-93.
- [2] Jordan A.M., *ACS Med. Chem. Lett.*, **2018**, 9, 1150-1152.
- [3] Lake F., *Future Drug. Discov.*, **2019**, 1, FDD19.
- [4] Mak et al., *Drug Discov. Today*, **2019**, 24, 773-780.
- [5] Jose et al., *Expert Opin. Drug Discov.*, **2021**, [DOI: 10.1080/17460441.2021.1909567].
- [6] C. Balakumar et al., *J. Biomol Struc. Dyn.*, **2018**, 36, 3687-3704.
- [7] Struble et al., *J. Med. Chem. Lett.*, **2020**, 63, 8667-8682.
- [8] Freedman D.H., *Nature*, **2019**, 576, S50-S53.
- [9] Hessler et al., *Molecules*, **2018**, 23, 2520.